Two early-phase Russian coronavirus vaccine trials have produced promising results, with participants experiencing no serious adverse effects and evidence of an antibody response.
Controversy greeted the announcement last monththat Russia had approved the world’s first Covid-19 vaccine – befo
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
